RxDoctor Payments Data

Jack Scariano, MD

Neurology · Knoxville, TNNPI 1255333977

Payments from drug & device makers

$20,774in general payments, 2019–2025

Across 1,089 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • Neurelis, Inc.$2K
  • Biogen$2K
  • Neurocrine Biosciences, Inc.$1K
  • Eisai Inc.$942
  • Amneal Pharmaceuticals LLC$833
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$760%
  • Food & beverage$20,680100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.144$3,373
Neurelis, Inc.86$1,974
Biogen103$1,850
Neurocrine Biosciences, Inc.53$1,282
Eisai Inc.60$942
Amneal Pharmaceuticals LLC48$833
Kyowa Kirin, Inc.43$826
Bristol Myers Squibb35$763
AbbVie(2 entities)43$616
Avanir Pharmaceuticals, Inc.35$598
Lilly USA, LLC32$526
Otsuka America Pharmaceutical, Inc.21$511
Novartis32$496
Teva Pharmaceuticals USA, Inc.22$481
Sanofi24$457
EMD Serono, Inc.26$446
Amgen26$428
MDD US Operations, LLC27$410
Acadia Pharmaceuticals Inc23$355
SK Life Science, Inc.18$352
AstraZeneca(2 entities)11$277
Greenwich Biosciences, Inc.9$225
Argenx US, Inc.10$219
Corium, LLC11$214
Scilex Pharmaceuticals Inc.12$201
Supernus Pharmaceuticals, Inc.22$199
Arbor Pharmaceuticals, Inc.10$168
Acorda Therapeutics, Inc9$154
Mallinckrodt Hospital Products Inc.7$129
Lundbeck LLC7$127
Johnson & Johnson7$113
Sumitomo Pharma America, Inc.9$98
Merz Pharmaceuticals, LLC4$94
Azurity Pharmaceuticals, Inc.5$88
Catalyst Pharmaceuticals, Inc.5$87
Genentech USA, Inc.5$82
Avion Pharmaceuticals5$80
E.r. Squibb & Sons, L.L.C.4$71
Adamas Pharmaceuticals, Inc.3$65
Biohaven Pharmaceuticals, Inc.3$50
Livanova USA, Inc.2$37
Akcea Therapeutics, Inc.2$36
Ipsen Biopharmaceuticals, Inc2$35
Jazz Pharmaceuticals Inc.2$35
Merz North America, Inc.1$35
Vanda Pharmaceuticals Inc.2$30
Biohaven Pharmaceutical Holding Company Ltd.2$30
Hospira, Inc.1$29
Upsher-smith Laboratories LLC2$28
Assertio Therapeutics, Inc.2$26
Averitas Pharma Inc.1$24
Currax Pharmaceuticals LLC2$23
Nevro Corp.1$20
Collegium Pharmaceutical, Inc.1$19
TG Therapeutics, Inc.1$18
Grifols USA, LLC1$18
Banner Life Sciences, LLC1$18
Medtronic1$17
Pfizer1$14
Sunovion Pharmaceuticals Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,774 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$158,176
Medicare patients
441
Services billed
1,443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate33$314,868
NuplazidPimavanserin Tartrate15$83,888
RytaryCarbidopa/Levodopa170$69,423
NuedextaDextromethorphan Hbr/Quinidine13$18,739
Aimovig AutoinjectorErenumab-Aooe14$12,276
Carbidopa-LevodopaCarbidopa/Levodopa1,023$12,188
SavellaMilnacipran Hcl12$5,269
Ropinirole Hcl253$4,066
AmantadineAmantadine Hcl47$3,065
Gabapentin370$2,747
Pregabalin136$1,828
Lacosamide28$1,428
Carbamazepine ErCarbamazepine13$1,312
Carbidopa-Levodopa ErCarbidopa/Levodopa28$1,302
Levetiracetam43$1,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$1,850$314,86833 claims
Acadia Pharmaceuticals IncNuplazid$355$83,88815 claims
Amneal Pharmaceuticals LLCRytary$833$69,423170 claims
Avanir Pharmaceuticals, Inc.Nuedexta$598$18,73913 claims
AbbVieSavella$616$5,26912 claims
Upsher-smith Laboratories LLCTopiramate$28$26030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →